Please login to the form below

Not currently logged in
Email:
Password:

Idera

This page shows the latest Idera news and features for those working in and with pharma, biotech and healthcare.

Big pharma and biotech M&A activity increases in Q4 2006

530. Idera. Merck. Toll-like Receptor (TLR) agonists. 455. AC Immune. Genentech.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    There are various companies working on toll-like receptor agonists that stimulate antigen-presenting cells, such as Idera’s TLR9-targeted drug IMO-2125 which boosted the activity of BMS’ CTLA4

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 235. Idera Pharmaceuticals/ Vivelix Pharmaceuticals. IMO-9200, antagonist of TLR 7, 8 and 9, for non-malignant GI disorders (p1) back ups.

  • Deal Watch November 2015 Deal Watch November 2015

    Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in renal disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ImmuneXcite boosts senior leadership ImmuneXcite boosts senior leadership

    He is chairman of the board of Idera Pharmaceuticals and Juniper Pharmaceuticals and has previously worked at Sanofi-Aventis and Genzyme.

  • Idera Pharmaceuticals names new CEO Idera Pharmaceuticals names new CEO

    He now takes charge of Idera, a clinical-stage biopharmaceutical company that also has an interest in rare diseases. ... Milano succeeds Sudhir Agrawal, who will remain at Idera as president of research and will serve on the company's board of directors.

  • Former Sanofi SVP to chair Idera Former Sanofi SVP to chair Idera

    Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion ... These programmes involve the company's

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics